ARCHIVES

Guest Editorial: caBIG Has Another Fundamental Problem: It Relies On “Incoherent” Messaging Standard

This article is from The Cancer Letter archive.

Vol. 37 No. 16 | April 22, 2011

Download PDF Visit The Full Archive

Related Articles

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

Waldmann, Columbia, Netherland, Receive Bristol-Myers Awards

April 17, 1992

FDA Describes Meeting With NCI In “Limited” Memo

May 7, 1976

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

Five Group Chairs Discuss Mergers In A Q&A

March 11, 2011

Regulatory Agencies: FDA Proposes “Treatment IDE” Funding Opportunities:

February 7, 1997